BioMarin Answers BridgeBio's Challenge with sNDA for Achondroplasia

BioMarin refuses to give BridgeBio ground in their battle for the achondroplasia market. Tuesday, the rare disease biotech announced the FDA has accepted its supplemental New Drug Application (sNDA) to expand Voxzogo (vosoritide) to children younger than five years.